EHA 2026 | Ponatinib consolidation may improve second treatment-free remission in CML
Gonzalo Carreño Gómez-Tarragona
• 12 Jun 2026
Gonzalo Carreño Gómez-Tarragona, MD, PhD, 12 de Octubre University Hospital, Madrid, Spain, presents updated findings from the ResToP trial (NCT04160546), showing that ponatinib consolidation before a second treatment-free remission attempt may improve the likelihood of maintaining molecular response after discontinuation in patients with chronic myeloid leukemia (CML). This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
